AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-914-8420
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Avrobio (NASDAQ:AVRO) Frequently Asked Questions
What is Avrobio's stock symbol?
Avrobio trades on the NASDAQ under the ticker symbol "AVRO."
How were Avrobio's earnings last quarter?
Avrobio Inc (NASDAQ:AVRO) issued its quarterly earnings data on Monday, May, 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.01. View Avrobio's Earnings History.
When is Avrobio's next earnings date?
What price target have analysts set for AVRO?
8 analysts have issued 1-year price objectives for Avrobio's stock. Their predictions range from $19.00 to $40.00. On average, they anticipate Avrobio's share price to reach $33.57 in the next twelve months. This suggests a possible upside of 119.1% from the stock's current price. View Analyst Price Targets for Avrobio.
What is the consensus analysts' recommendation for Avrobio?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.
What are Wall Street analysts saying about Avrobio stock?
Here are some recent quotes from research analysts about Avrobio stock:
- 1. According to Zacks Investment Research, "Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States. " (2/20/2019)
- 2. HC Wainwright analysts commented, "Our $40 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF analysis, which is based on: beta of 1.15, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.5%, and tax rate of 15% beginning in FY 2028. Our price target reflects uncertainties stemming from the clinical update from the Fabry program (AVR-RD-01), resulting in: (1) a push out of our launch estimate into 2H-2022, vs. prior 2H-2021; and (2) lower Fabry POS of 25% from 30%." (1/15/2019)
Has Avrobio been receiving favorable news coverage?
News articles about AVRO stock have been trending neutral recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avrobio earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Avrobio's key competitors?
Some companies that are related to Avrobio include Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Regenxbio (RGNX), Alector (ALEC), Rubius Therapeutics (RUBY), Coherus Biosciences (CHRS), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), NanoString Technologies (NSTG), Autolus Therapeutics (AUTL), GENFIT S A/ADR (GNFT) and Voyager Therapeutics (VYGR).
What other stocks do shareholders of Avrobio own?
Who are Avrobio's key executives?
Avrobio's management team includes the folowing people:
- Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 53)
- Mr. Steven N. Avruch, VP, Gen. Counsel & Sec. (Age 58)
- Mr. Jeffrey Medin Ph.D., Scientific Founder
- Mr. Erik Ostrowski, CFO & Treasurer (Age 46)
- Dr. Kim Warren, Head of Operations
When did Avrobio IPO?
(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.
Who are Avrobio's major shareholders?
Avrobio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (5.08%), BlackRock Inc. (4.35%), Aisling Capital Management LP (3.36%), Wellington Management Group LLP (2.98%), Emerald Advisers LLC (2.55%) and Emerald Mutual Fund Advisers Trust (2.17%). Company insiders that own Avrobio stock include Christopher Paige and Geoffrey Mackay. View Institutional Ownership Trends for Avrobio.
Which institutional investors are selling Avrobio stock?
AVRO stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Citigroup Inc. and TD Asset Management Inc.. Company insiders that have sold Avrobio company stock in the last year include Christopher Paige and Geoffrey Mackay. View Insider Buying and Selling for Avrobio.
Which institutional investors are buying Avrobio stock?
AVRO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Wellington Management Group LLP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Victory Capital Management Inc., Aisling Capital Management LP and Goldman Sachs Group Inc.. View Insider Buying and Selling for Avrobio.
How do I buy shares of Avrobio?
Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avrobio's stock price today?
One share of AVRO stock can currently be purchased for approximately $15.32.
How big of a company is Avrobio?
Avrobio has a market capitalization of $369.93 million. The company earns $-46,360,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis. Avrobio employs 49 workers across the globe.
What is Avrobio's official website?
How can I contact Avrobio?
Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]
MarketBeat Community Rating for Avrobio (NASDAQ AVRO)
MarketBeat's community ratings are surveys of what our community members think about Avrobio and other stocks. Vote "Outperform" if you believe AVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
